Effects of nicotine nasal spray on atherogenic and thrombogenic factors during smoking cessation.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

To investigate changes in cardiovascular risk factor parameters when stopping smoking and to identify any impact of nicotine nasal spray on these factors.

Who Took Part

According to the abstract, 157 subjects were involved.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

In a placebo-controlled, double-blind 3-month prospective study, nicotine nasal spray (NNS) or a placebo was given to 157 subjects attending a smoking cessation programme.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Neither the subjects nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.

Nasal spray use was given on an ad libitum basis.

What Was Measured

PubMed files the paper under topics including Administration, Inhalation, Arteriosclerosis, Cardiovascular Diseases, Cholesterol, Erythrocyte Indices, Fibrinogen and Hematocrit.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 157 subjects.

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1999 (Journal of internal medicine), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.